ArticleAntimicrobial agents and chemotherapy2019
ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
4.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.Health technology assessment (Winchester, England) · 2024Pooled it
- Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.Frontiers in microbiology · 2024Pooled it
- The prevalence of colistin resistance in clinical Stenotrophomonas maltophilia isolates worldwide: a systematic review and meta-analysis.BMC microbiology · 2023Pooled it
- Impact of medium composition on cefiderocol susceptibility testing: comparison of CLSI/EUCAST-compliant and commercial broth microdilution methods.JAC-antimicrobial resistance · 2026Article
- Vitamin B12 promotes cefiderocol resistance and small-colony variants in carbapenem-resistantmBio · 2026Article
- The Therapeutic Potential of Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Narrative Review.Journal of clinical medicine · 2025Review
- Global Epidemiology and Antimicrobial Resistance of Klebsiella Pneumoniae Carbapenemase (KPC)-Producing Gram-Negative Clinical Isolates: A Review.Microorganisms · 2025Review
- Resistance to oxyimino-cephalosporins conferred by an alternative mechanism of hydrolysis by themBio · 2025Article
- Effects of different carbapenemase and siderophore production on cefiderocol susceptibility inAntimicrobial agents and chemotherapy · 2024Article
- ARGONAUT-IV: susceptibility of carbapenemase-producingAntimicrobial agents and chemotherapy · 2024Article
- In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2024Article
- ARGONAUT-III and -V: susceptibility of carbapenem-resistantAntimicrobial agents and chemotherapy · 2024Article
- Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria.Communications medicine · 2024Review
- Insights into the activity of cefiderocol against PER-2 producing Enterobacterales.Antimicrobial agents and chemotherapy · 2024Article
- Article
- Role of transcriptomic and genomic analyses in improving the comprehension of cefiderocol activity inmSphere · 2024Article
- Impact of pH on the activity of novel cephalosporin cefiderocol in human urine.The Journal of antimicrobial chemotherapy · 2024Article
- Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.Annals of intensive care · 2023Review
- The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference.Annals of intensive care · 2023Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Michael R JacobsDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA mrj6@case.edu robert.bonomo@va.gov.
Ayman M AbdelhamedDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Caryn E GoodDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.
Daniel D RhoadsDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-7636-5191
Kristine M HujerDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Andrea M HujerDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
T Nicholas DomitrovicDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Susan D RudinDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Sandra S RichterDepartment of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
David van DuinDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4784-3227
Barry N KreiswirthPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Chris GrecoJ. Craig Venter Institute, Rockville, Maryland, USA.
Derrick E FoutsJ. Craig Venter Institute, Rockville, Maryland, USA.
Robert A BonomoDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA mrj6@case.edu robert.bonomo@va.gov.
Louis Stokes Cleveland VA Medical Center · USUniversity Hospitals of Cleveland · USJ. Craig Venter Institute · USCleveland Clinic · USRutgers, The State University of New Jersey · USUniversity of North Carolina at Chapel Hill · US
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MThe J. Craig Venter Institute Genome Center for Infectious DiseasesU19AI110819 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI TAN, GENE · 2014 to 2018
$29.7MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MMolecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R21 AI114508NIAID NIH HHS U19 AI110819NIAID NIH HHS UM1 AI104681
Abstract
The activity of the siderophore cephalosporin cefiderocol is targeted against carbapenem-resistant Gram-negative bacteria. In this study, the activity of cefiderocol against characterized carbapenem-resistant
Indexed as
Acinetobacter baumanniiAnti-Bacterial Agentsbeta-Lactamasesbeta-Lactam ResistanceCefiderocolCephalosporinsCulture MediaEnterobacteriaceaeGene ExpressionGram-Negative Bacterial InfectionsHumansMicrobial Sensitivity TestsPseudomonas aeruginosaSiderophoresStenotrophomonas maltophiliaAnti-Bacterial Agentsbeta-LactamasesCefiderocolCephalosporinsCulture MediaSiderophorescefiderocolcephalosporinEnterobacteriaceaeGram-negative bacteriaS-649266siderophore
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.